Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension.

Brown, Robert S; Collins, Michelle A; Strasser, Simone I; Emmett, Amanda; Topp, Andrew S; Burroughs, Margaret; Ferreira, Rosa; Feld, Jordan J

Brown, Robert S; Collins, Michelle A; Strasser, Simone I; Emmett, Amanda; Topp, Andrew S; Burroughs, Margaret; Ferreira, Rosa; Feld, Jordan J.

Afiliación

Brown RS; Center for Liver Disease and Transplantation, Weill Cornell Medical College, 1305 York Avenue, New York, NY, 10021, USA. rsb2005@med.cornell.edu.
Collins MA; AbbVie Inc., North Chicago, IL, USA.
Strasser SI; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Emmett A; AbbVie Inc., North Chicago, IL, USA.
Topp AS; AbbVie Inc., North Chicago, IL, USA.
Burroughs M; AbbVie Inc., North Chicago, IL, USA.
Ferreira R; AbbVie Inc., North Chicago, IL, USA.
Feld JJ; Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON, Canada.

Infect Dis Ther ; 11(2): 913-924, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35174470

Palabras clave

Glecaprevir; Hepatitis C; Pibrentasvir; Portal Hypertension; Sustained Virologic Response

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Infect Dis Ther Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google